Skip to main content

Research Repository

Advanced Search

Blood test for clinical therapy guidance of non-small cell lung cancer patients

People Involved

Project Description

Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy. Currently, the laboratories use PCR and Sanger sequencing technologies to perform the EGFR analysis from tumour biopsies – Fixed Paraffin Embedded (FFPE) samples. Still, some patients (e.g., 30% in UK) may never get histological confirmation because they are too sick to make a biopsy. Furthermore, the results obtained with current methods still present low quality, mainly due to poor quality/low yield of DNA extracted from FFPE samples. The FP7 LungCARD project (www.lungcard.eu) has developed and demonstrated a LungCARD system - an automatic system composed by microfluidic chip and chip analyser - that allows to capture circulating tumour cells (CTCs) from blood samples, amplify by multiplex PCR and detect EGFR mutations, including also a software for data analysis and report. Although this new blood test has proven to be faster, cost-effective and human error-free, the detection of somatic mutations in EGFR gene at frequencies lower than 20% is still a weak point.

Therefore, the main project’s goal is to benefit from this technology, through the development, improvement, integration and validation of the LungCARD system with NGS workflow and development of a software for automatic reporting clinical results. However, LungCARD project aims to go further, by putting together a global and unique network of multidisciplinary scientists for exchange of knowledge and research training focused on non-small cell lung cancer.

University of Hull is one of sixteen partners for this H2020 project.

Project Acronym LungCARD
Status Project Complete
Value £144,000.00
Project Dates Jan 1, 2017 - Oct 31, 2022
Partner Organisations University of Hassan II Casablanca
Sloan Kettering Institute for Cancer Research
Institut Pasteur du Maroc
University of Technology Sydney
National Cancer Center of Uzbekistan
Universidad de San Martín de Porres
National Centre of Oncology
Paresq Lab Co Ltd
Federal University of Agriculture, Abeokuta

You might also like

The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture. Jun 1, 2017 - May 31, 2018
Graves’ disease (GD) affects approximately 2% of adult women. Current treatments for GD include anti-thyroid drugs, radioiodine therapy and surgery, of which none tackle the underlying pathogenic process. Immunosuppressive agents are therefore of gro... Read More about The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture..